Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2018-09-27 Regulatory Filings
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about clinical trial data and additional information exhibits, but it does not contain comprehensive financial statements or detailed financial analysis. It is not an earnings release or annual/interim report. The document is a regulatory announcement of a material event, specifically clinical trial results, which fits the category of Regulatory Filings (RNS) as a general SEC filing that does not fit other specific categories. The document length is just over 5,000 characters but contains no substantive financial data or management discussion, confirming it is a regulatory announcement rather than a financial report.
2018-09-27 English
FORM 4 SUBMISSION
Director's Dealing
2018-09-21 English
FORM 3 SUBMISSION
Director's Dealing
2018-09-21 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-09-19 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2018, by Spero Therapeutics, Inc. The content focuses on the departure of a board member and the appointment of a new director, including biographical details and governance compliance statements. There are no financial statements or earnings data presented. The primary subject is changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is over 6,000 characters, so it is not a brief announcement of a report publication. Therefore, the correct classification is MANG with high confidence.
2018-08-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2018, reporting the results of operations and financial condition for the quarter ended June 30, 2018. It specifically states that the company issued a press release announcing its quarterly results, and the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3076 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results.
2018-08-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.